| Dr Lee Michael Stenzler, MD | |
|
1801 E March Ln, Ste D400, Stockton, CA 95210 | |
| (209) 464-3615 | |
| (209) 464-1311 |
| Full Name | Dr Lee Michael Stenzler |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 41 Years |
| Location | 1801 E March Ln, Stockton, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124096177 | NPI | - | NPPES |
| 00G535850 | Medicaid | CA | |
| G53585 | Other | CA | MEDICAL LICENSE NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | G535850 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dameron Hospital | Stockton, CA | Hospital |
| Adventist Health Lodi Memorial | Lodi, CA | Hospital |
| St Joseph's Medical Center Of Stockton | Stockton, CA | Hospital |
| University Of California Davis Medical Center | Sacramento, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Adventist Health Physicians Network | 3274580972 | 499 |
| Regents Of The University Of California | 8022922475 | 462 |
News Archive
Losing weight - especially when the goal is to lose double-digit amounts - can seem like a daunting task, but a health and wellness expert at the University of Alabama at Birmingham (UAB) said the key is to take it one step at a time.
Ronald Lindquist, 87, has been active all his life. So, he wasn't prepared for what happened when he stopped going out during the coronavirus pandemic and spent most of his time, inactive, at home.
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
The Atlantic examines the issue of violence against pregnant women in India. "In the aftermath of the high-profile gang rape of a 23-year-old medical student, discussions have raged in India about the regularity of violence against women," the magazine writes, adding, "As has been widely noted, the causes of the violence run deep. But they also are broad."
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
› Verified 7 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952998973 PECOS PAC ID: 8022922475 Enrollment ID: O20031118001149 |
News Archive
Losing weight - especially when the goal is to lose double-digit amounts - can seem like a daunting task, but a health and wellness expert at the University of Alabama at Birmingham (UAB) said the key is to take it one step at a time.
Ronald Lindquist, 87, has been active all his life. So, he wasn't prepared for what happened when he stopped going out during the coronavirus pandemic and spent most of his time, inactive, at home.
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
The Atlantic examines the issue of violence against pregnant women in India. "In the aftermath of the high-profile gang rape of a 23-year-old medical student, discussions have raged in India about the regularity of violence against women," the magazine writes, adding, "As has been widely noted, the causes of the violence run deep. But they also are broad."
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
› Verified 7 days ago
| Entity Name | Pacific Heart And Vascular Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649208463 PECOS PAC ID: 1658267190 Enrollment ID: O20040223001067 |
News Archive
Losing weight - especially when the goal is to lose double-digit amounts - can seem like a daunting task, but a health and wellness expert at the University of Alabama at Birmingham (UAB) said the key is to take it one step at a time.
Ronald Lindquist, 87, has been active all his life. So, he wasn't prepared for what happened when he stopped going out during the coronavirus pandemic and spent most of his time, inactive, at home.
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
The Atlantic examines the issue of violence against pregnant women in India. "In the aftermath of the high-profile gang rape of a 23-year-old medical student, discussions have raged in India about the regularity of violence against women," the magazine writes, adding, "As has been widely noted, the causes of the violence run deep. But they also are broad."
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
› Verified 7 days ago
| Entity Name | Adventist Health Physicians Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063718583 PECOS PAC ID: 3274580972 Enrollment ID: O20050407000633 |
News Archive
Losing weight - especially when the goal is to lose double-digit amounts - can seem like a daunting task, but a health and wellness expert at the University of Alabama at Birmingham (UAB) said the key is to take it one step at a time.
Ronald Lindquist, 87, has been active all his life. So, he wasn't prepared for what happened when he stopped going out during the coronavirus pandemic and spent most of his time, inactive, at home.
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
The Atlantic examines the issue of violence against pregnant women in India. "In the aftermath of the high-profile gang rape of a 23-year-old medical student, discussions have raged in India about the regularity of violence against women," the magazine writes, adding, "As has been widely noted, the causes of the violence run deep. But they also are broad."
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lee Michael Stenzler, MD 1801 E March Ln, Ste D400, Stockton, CA 95210 Ph: (209) 464-3615 | Dr Lee Michael Stenzler, MD 1801 E March Ln, Ste D400, Stockton, CA 95210 Ph: (209) 464-3615 |
News Archive
Losing weight - especially when the goal is to lose double-digit amounts - can seem like a daunting task, but a health and wellness expert at the University of Alabama at Birmingham (UAB) said the key is to take it one step at a time.
Ronald Lindquist, 87, has been active all his life. So, he wasn't prepared for what happened when he stopped going out during the coronavirus pandemic and spent most of his time, inactive, at home.
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
The Atlantic examines the issue of violence against pregnant women in India. "In the aftermath of the high-profile gang rape of a 23-year-old medical student, discussions have raged in India about the regularity of violence against women," the magazine writes, adding, "As has been widely noted, the causes of the violence run deep. But they also are broad."
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
› Verified 7 days ago
Jasmine Hundal, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7210 Murray Dr, Stockton, CA 95210 Phone: 209-751-1919 | |
Dr. Navneet Kaur, M.B.B.S Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1805 N California St Ste 201, Stockton, CA 95204 Phone: 209-645-4005 Fax: 209-645-6344 | |
David C Lim, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 415 E Harding Way, Suite D, Stockton, CA 95204 Phone: 209-944-5750 | |
Xing-jian Lu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 7373 West Ln, Stockton, CA 95210 Phone: 209-476-2000 | |
Kwabena Opoku-mensah Adubofour, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2524 E Main St, Stockton, CA 95205 Phone: 800-249-9497 Fax: 800-249-9497 | |
Dr. Ronald A Kass, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1801 E March Ln Ste C310, Stockton, CA 95210 Phone: 209-465-5731 Fax: 209-465-0230 | |
Issa M. Fakhouri, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 7373 West Ln, Stockton, CA 95210 Phone: 209-476-2000 |